The AGENT Study is conducted at nearly 80 research centers throughout the U.S., Canada and western Europe. This global study is a Phase 3 clinical trial evaluating arfolitixorin as a first-line treatment of metastatic colorectal cancer (mCRC).
Colorectal cancer (CRC) is one of the most common forms of cancer with more than 1.8 million new cases identified globally every year. There have been no significant advances in the treatment of CRC for decades. Arfolitixorin is a new experimental therapy being developed to improve the effectiveness of standard of care chemotherapy for patients living with mCRC.
Information in relation to COVID-19
The spread of the COVID-19 pandemic is a major public health issue affecting societies and companies all over the world and will have a significant impact on the global healthcare systems. Isofol’s top priority is to ensure the safety of patients, healthcare professionals, employees and suppliers involved in the ongoing AGENT study.
Leading national and global health organizations, regulatory agencies, healthcare systems and countries are actively updating their guidelines, including guidance around ongoing clinical trials, and Isofol is taking necessary steps to fully comply with new guidance. The company has taken proactive measures to ensure continuity of the global Phase 3 AGENT study, which will continue to enroll patients in line with regulatory guidelines and site capabilities.
We encourage everyone to stay safe by following measures outlined by your local authorities and health officials. Please stay tuned for further updates. If you have any questions regarding the impact of the pandemic on the AGENT study, please contact us for more information.